Efficacy
Tumors, PD, tumor, Tumor
DISEASE, TUMOR, TUMOR, TUMORS
Overall, a PR was observed in 4 of the 25 patients (16.0%; Summary of tumor responses (per Investigator Review by RECIST v1.1)Abbreviations: BOR, best overall response; CI, confidence interval; CR, complete response; DCR, disease control rate; E7389-LF, eribulin liposomal formulation; NE, not evaluable; ORR, objective response rate; PD progressive disease; PR, partial response; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SD, stable disease.




Maximum percentage change from baseline in sums of tumor diameters and best overall response per RECIST v1.1. E7389-LF, eribulin liposomal formulation; PD, progressive disease; PR, partial response; Q#W, every # weeks; RECIST v1.1, Response Evaluation Criteria In Solid Tumors, version 1.1; SD, stable disease.Percentage changes from baseline in sums of target lesion diameters over time per RECIST v1.1 by investigator assessment. Tumor types of patients with at least a 30% reduction at any timepoint are listed. 